معرفی
Professor Andrew Tee is a leading academic and researcher in Cardiff University's School of Medicine, Division of Cancer and Genetics. He holds a BSc (Hons) and PhD from the University of Dundee. His research focuses on mTOR signaling pathways, genetic disorders like Tuberous Sclerosis Complex (TSC), Birt-Hogg-Dubé (BHD), and Neurofibromatosis, and their implications in cancer biology. His work has led to clinical trials using mTOR inhibitors for TSC patients and explores novel therapies for sporadic cancers.
Key research interests include understanding how mutations in tumor suppressor genes like TSC1/TSC2 and FLCN disrupt mTOR signaling, driving tumor formation and metabolic dysregulation. Recent projects investigate ferroptosis resistance in TSC2-deficient cells, transcriptomic/proteomic analysis of BHD syndrome, and biomarkers in Graves' Orbitopathy.
Professor Tee's grants and collaborations include funding from the Tuberous Sclerosis Association, Myrovlytis Trust, and pharmaceutical companies like Apexian and GW/JAZZ. His lab includes postdoctoral researchers, PhD students, and technicians. Notable achievements include identifying mTOR's role in HIF-1α and STAT3 signaling and discovering therapeutic synergies with nelfinavir and bortezomib for TSC-related tumors.
Scientific accolades include EMBO and BHF Fellowships, and he serves on editorial boards for Cancers and Seminars in Cell and Developmental Biology. His future work aims to translate rare disease insights into broader cancer therapies and predictive biomarker strategies.
